In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biohaven nets $303mm through FOPO

Executive Summary

Neuro-focused Biohaven Pharmaceutical Holding Co. Ltd. netted $303mm in a public offering of 7.5mm shares (including partial exercise of the overallotment) at $43. The company will use the proceeds to support continued and expanded development of its three platforms: calcitonin gene-related peptide (CGRP) receptor antagonists; glutamate modulators; and myeloperoxidase (MPO) inhibitors. An NDA submission is expected in mid-2019 for its most advanced CGRP candidate rimegepant (in Phase III for migraine) using a priority review voucher (PRV) Biohaven bought earlier this year from GW Pharmaceuticals, allowing the former to designate a single NDA for priority status and providing an accelerated six-month review period.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies